PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug
• PTC Therapeutics said it cannot resolve differences it has with the FDA in interpreting clinical trial data for Translarna, a drug it developed for Duchenne muscular dystrophy. •